Compare CETX & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CETX | PTIX |
|---|---|---|
| Founded | 1998 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5M | 3.2M |
| IPO Year | 1998 | 2016 |
| Metric | CETX | PTIX |
|---|---|---|
| Price | $4.27 | $1.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 108.3K |
| Earning Date | 12-29-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,095,551.00 | N/A |
| Revenue This Year | $19.77 | N/A |
| Revenue Next Year | $15.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.50 | N/A |
| 52 Week Low | $2.50 | $1.46 |
| 52 Week High | $55.50 | $14.28 |
| Indicator | CETX | PTIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.51 | 31.07 |
| Support Level | $2.50 | $1.46 |
| Resistance Level | $9.70 | $2.38 |
| Average True Range (ATR) | 0.96 | 0.19 |
| MACD | 0.24 | -0.01 |
| Stochastic Oscillator | 25.00 | 21.80 |
Cemtrex Inc is a multi-industry technology company. It has expanded in a range of sectors, including smart technologies, virtual and augmented realities, industrial solutions, and intelligent security system. The company's operating segment includes, Security segment, Industrial Services segment and the corporate segment. The security segment provides end to end security to all industrial, corporate and governmental security via owned subsidiary Vicon. Whereas AIS part Industrial Service Segment is expertise services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. It generates maximum revenue from the Industrial Service Segment. It geographically operates in USA, UK and India, with maximum of revenue from USA.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.